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11   Introduction 
1 Introduction: Prenatal screening, Invasive and Non-
invasive Diagnosis. 
12   Introduction 
Prenatal screening is carried out to detect pregnancies at risk for fetal anomalies, specifically 
chromosomal anomalies such as trisomy 21 (Down Syndrome)(figure 1), trisomy 18 
(Edwards Syndrome) and trisomy 13 (Patau Syndrome) [1]. 
 
 
Figure 1. Karyotype from a female with Down syndrome. The red arrow indicates the triplication of 
chromosome 21. Image adapted from Clinical Tools, Inc. 
 
Prenatal screening is a routine procedure in current obstetric practices. The first method 
introduced in the screening was advanced maternal age, as it was known for long time that 
advanced maternal age is associated with an increased risk of having a trisomic baby [2]. It 
has being shown that chances of having trisomy baby is about 2% in the women under 25 
years, but it increase to 35% in women over 40 years (Figure.2) [3]. 
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Figure 2. Maternal age and trisomy. This shows the maternal-age-specific estimates of trisomy among all 
clinically recognized human pregnancies. Graph adapted from Nature Reviews in Genetics, 2001 (Hassold T et 
al). 
 
In the developed world, due to the change in demographics many women are older when 
having children, with many women above 35 years at the time of first pregnancy [4]. As 
discussed above, an advance in maternal age is one of the criteria for the prenatal screening. 
In a recent longitudinal [5] study carried out (1998-2008) on women in the UK, a 71% 
increase in the number of Down Syndrome (DS) cases was observed (Figure.3). As women at 
risk of carrying a fetus with a chromosomal anomaly, as identified by screening procedures, 
are encouraged to undergo an invasive prenatal diagnostic procedure, this will be a big health 
care burden. 
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Figure 3. 71% increase in the number of pregnancies carrying a fetus with Down's syndrome in the period of 
1990 till 2006. Graph adapted from BMJ, 2009 (Morris J K et al). 
 
Current prenatal screening tests for the detection of pregnancies at risk of bearing a fetus with 
a chromosomal anomaly are carried out in 1st trimester (11-13 weeks of gestation). Hence, 
this procedure is also known as the 1st trimester screen. This non-invasive screening test 
largely relies on the ultrasound analysis of the nuchal fold of the fetus neck, also called nuchal 
translucency (NT), which is increased in DS fetuses. (Figure.4). If the nuchal fold is thicker 
then average, it is considered as a high risk pregnancy for a chromosomal anomaly. On its 
own, the NT screening test can detect approximately 75 % of DS fetuses, but is hampered by 
a high false positive rate (> 5%). 
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Figure 4. Nuchal Translucency Scan: Increased nuchal fold in the neck of DS fetus. Scan adapted from 
www.obgyn.net  
 In order to improve the accuracy of this test, current 1st trimester screens combine ultrasound 
NT measurements with maternal serum markers such as beta-hCG (Beta-Human Chorionic 
Gonadrotropin) and PAPP-A (Pregnancy-associated Plasma Protein A) for DS screening. 
These serum proteins are shown to be elevated in the maternal serum with DS pregnancy. 
This approach is known as the combined test, which yield a detection rate of approximately 
80%, with significantly reduced false positive rate of around 5%.  
The combined 1st trimester screening test is a great improvement over the previous 2nd 
trimester screen, which had a false positive rate (8-10%) and a detection rate of only 65%. 
Hence, the combined test in 1st trimester is routine practice for DS screening in many centres 
worldwide.  
Those pregnancies which are screen positive are counselled to consider an invasive prenatal 
examination. Currently invasive procedure includes Chorionic Villous Sampling (CVS) or 
Amniocentesis, which are described in detail later (refer to section 1). The main drawback 
with 1st trimester screen is large number of false positive cases that are detected, and that these 
healthy pregnancies are unnecessarily subjected to an invasive prenatal diagnostic procedure. 
Since the risk of fetal loss calculated for invasive procedure is around 1%, this implies that a 
lot of fetuses are exposed to an unnecessary risk due to the current high false positive rate. In 
reality, this means that a large number of healthy babies are lost due to this problem. 
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In order to increase the accuracy of the 1st trimester screening test, a number of efforts have 
been undertaken to increase efficacy and accuracy of the current procedure. This includes the 
inclusion of a number of additional serum screening markers such as the inhibin, or 
ultrasonography for the fetal nasal bone. Unfortunately, these have not lead to the desired 
reduction in the FP rate. 
Hence, it has become obvious that there is a need for additional biomarkers, which can add 
more to the sensitivity and specificity of current non-invasive screening procedure. 
This aspect forms the major aim of this thesis.  
 
1.1  Current invasive procedures for prenatal diagnosis. 
1.1.1 Amniocentesis:  
In this procedure amniotic fluid (AF) is obtained from the fetal amnion, which contains 
amniotic cells that can be used to determine whether a fetal chromosomal abnormality of 
developing fetus is present. The procedure is performed under ultrasound guidance, whereby 
a thin canulla is inserted into the amniotic sac and a volume of 15-20 ml of AF is collected 
using a standard syringe.  The procedure is usually done after 16 weeks of pregnancy. 
Conventionally, the chromosomal analysis relies on karyotyping of cultured AF cells, a 
procedure which can take up to 2 weeks. In order to improve the speed of the diagnosis, many 
labs now offer direct fluorescent in situ hybridization (FISH) or QF-PCR (quantitative 
fluorescence polymerase chain reaction) of uncultured AF cells [6].  
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Figure 5.Transabdominal Amniocentesis procedure (2008 Nucleus Medical Art, Inc.) 
1.1.2 Chorionic villus sampling 
 During Chorionic villous sampling (CVS), a sample from the villi of the placenta, as this 
material contains cells with the same genetic composition as the developing fetus. The 
advantage of CVS is that it can be done in first trimester. Hence, it is a method of choice for 
the karyotyping or molecular diagnosis of inherited disorders such as the hemoglobinopathies 
in early gestation. Akin to amniocentesis, it is performed under ultrasound guidance, either 
transabdominally or transcervically, to determine fetal position, placental location and 
amniotic fluid volume. 
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Figure 6. Transabdominal Chorionic Villous Sampling (Adapted from ADAM) 
 
Due to the intricacy of the operation, CVS requires more skilled staff to perform it than AC. 
A confounder with CVS is confined placental mosaicism (CPM), which is one of the major 
problems in placental samples, as it can impose serious questions when the discrepancy 
between the chromosomal makeup of the cells in the placenta and the fetus are dissimilar. 
CPM is detected in approximately 1-2 % of ongoing pregnancies that are studied by CVS. 
There are also some indications that CVS may be more dangerous than amniocentesis. Other 
complications, which are common to AC includes infection, vaginal bleeding and uterine 
irritability. 
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1.2 Non-invasive prenatal diagnosis:  
 
Due to the risk associated with invasive procedures, a large research effort has been expended 
to the development of risk free alternatives. Current results indicate that we may be 
approaching the long sought goal of Non-Invasive Prenatal Diagnosis (NIPD), whereby it will 
be possible to identify hereditary single gene disorders or a chromosomal abnormality in the 
growing fetus.  
One of the routes explored for NIPD was via the enrichment of fetal cells, specifically 
erythroblasts, from maternal blood. After the enrichment, the putative fetal cells were 
examined by FISH analysis for the presence of a chromosomal anomaly. In the large a multi-
centre NIFTY study it was concluded that although promising, the sensitivity and specificity 
was below the required clinical application.  
A new avenue was provided by the detection of fetal cell-free DNA (cf-DNA) in maternal 
plasma or serum [7, 8]. The advantage of this approach is that cff-DNA is more abundant than 
fetal cells in maternal circulation. It is, however, hampered by the overwhelming presence of 
maternal cell free DNA.  
In order to overcome this deficit, our laboratory examined for possible biochemical 
differences between maternal and fetal cf-DNA fragments. Here we made the striking 
observation that a difference in the size exists between the fetal and maternal cf-DNA 
fragments, in that the fetal fragments were smaller than maternal ones. We showed that this 
difference could be used to selectively enrich the fetal cf-DNA sequences, thereby permitting 
the detection of otherwise masked fetal loci, such as point-mutations or polymorphisms which 
could assist with the determination of fetal aneuploidies [9]. In order for this approach to 
become clinically practical, the enrichment procedure will need to be optimized and 
automated. 
Other attempts to overcome this drawback rely on epigenetic differences between mother and 
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fetus, such as the maspin gene on chromosome 18 or the RASF1 gene [10]. Epigenetic 
approaches are currently hindered by inefficient methods such as bisulfite conversion, which 
leads to massive loss of epigenetically modified target DNA.  
A further approach being explored is that of cell-free mRNA of placental origin, such as that 
of the PLAC4 gene, which is located on chromosome 21. In a small pilot study, it has been 
suggested that it may be possible to detect DS by such means [11]. However, this approach is 
hampered by the instability of the placentally-derived mRNA, cost of processing and 
shipment requiring dry-ice.  
These facets are discussed in an invited review we wrote on new developments for NIPD of 
chromosomal anomalies and single gene disorders (see publications) [12]. In this we also 
describe the new strategies, such a next generations sequencing and digital PCR, being 
explored in this field 
1.3 Mass spectroscopy based proteomics 
Proteomics is defined as the analysis of whole protein component of a tissue (e.g. brain), cell 
(e.g. yeast) or a body fluid (blood or urine). More precisely it involves the determination of 
identity of the protein present in the mixture and its relative and absolute quantity. Recently it 
is also used to identify protein modifications (e.g. phosphorylation, glycosylation). 
Applications of proteomics are very wide, with the major application in clinical research 
being applied for the better understanding of biological processes and disease state. Examples 
are, to find and validate new biomarkers (diagnostic and prognostic) or to understand the 
pharmacodynamics and pharmacokinetics of a drug compound. 
A specific proteome is very dynamic and can provide lot of information on the expression 
pattern on normal vs. disease or control vs. treated. To study the proteome in its complexity, 
advanced tool are required, and in this context mass spectroscopy has emerged as a powerful 
technique for proteomic analysis. 
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A typical mass spectroscopy based proteomics workflow involves the digestion of protein in-
gel or in liquid. Online or off-line fractionation of the peptides is performed by liquid 
chromatography (LC) and followed by ionization. The peptides are converted into ions and 
mass analysis is done on these ions, following which the mass to charge ratio is recorded. The 
resulting fragment masses is used to search of large protein databases search, resulting in the 
identification of the peptide and protein (Figure.7)  
 
 
Figure 7. Typical workflow of mass spectroscopy based proteomics (adapted from Gstaiger M et al., Nature 
Review, Genetics 2009) 
 
1.4 Plasma proteomics for new screening biomarkers  
Plasma is an attractive entity for the proteomics studies. It contains different proteins from the 
various organs in high or low abundance. Many pathology or disease associated proteins are 
often present in plasma. Due to there low abundance, a number of different strategies have 
been developed to detect these in the plasma proteome, of which a few are discussed below.   
1.4.1 Two-dimensional gel electrophoresis (2-DE) 
Two-dimensional gel electrophoresis was introduced in 1975 by Klose and O’Farrell. 2-DE 
involves the separation of the protein in first dimension according to the isoelectric point (pI) 
by isoelectric focussing and in second dimension by molecular weight by running it on 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After staining the 
gel and comparing it with the control gel, differential spots are located, excised and analyzed 
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using the mass spectroscopy. The major drawback of this strategy is that the resolution of the 
protein spots for plasma is poor. This is because the most abundant plasma proteins like 
albumin, IgG, IgM mask the low abundant proteins. The reproducibility and sensitivity is low 
and it is very difficult to use 2DE for quantitative analysis.  
 
Figure 8. 2D gel for Human plasma, after the electrophoretic run gel was stained with sliver satin  
1.4.2 2-D Differential Gel Electrophoresis (2D DIGE) 
In traditional 2D gel electrophoresis the most preferred staining method is by Coomassie 
Brilliant Blue (CBB) or sliver stains. After staining intensity of the protein spot is used for 
relative quantitation when compare with the gel which is run in parallel. But CBB has poor 
detection sensitivity, where as sliver stain is not compatible with the down stream mass 
spectroscopy analysis. To over come this problem the proteins were label with fluorescent 
cyanine dye (cy2, cy3 and cy5) before the 2D separation. This method in know as 2-D 
differential gel electrophoresis (2D DIGE) to avoid the gel to gel variation. In same gel one 
can run control and experimental sample as well the internal standard. Internal standard is 
made by mixing equal amount of control and experimental sample and is used for the relative 
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quantitation (Figure.9). After the run the gel is scanned with the special Typhoon variable 
mode imager and DeCyder software is used for the differential analysis. 
 
 
Figure 9. Workflow of 2D-DIGE (adapted from GE health care) 
 
1.4.3 Isobaric Tagging for Relative and Absolute Quantitation (iTRAQ) 
Over a decade MS has evolved as a powerful technique. This has lead to the development of 
shotgun proteomics, which is a useful tool as it bank ready quantification using special 
reagent and technique. Lately there are different techniques available for the labeling which 
enables the quantification of the protein like stable isotope labeling of amino acid in cell 
cultures (SILAC) [13, 14], isotopic-coded affinity tags (ICAT) and isobaric tags for relative 
and absolute quantitation (iTRAQ) [15] 
iTRAQ is an isobaric chemical labeling approach currently the only technique capable of 
multiplexing up to eight different samples for relative quantification. 8-plex chemically 
identical iTRAQ reagents are available, named 114, 115, 116, 117, 118, 119, and 121 which 
have the same overall mass. Each label is composed of a peptide reactive group (NHS ester) 
and an isobaric tag of 145 Da that consists of a balancer group (carbonyl) and a reporter group 
(based on N-methyl piperazine), between the balancer and the reporter group is a 
fragmentation site (Figure.10). The peptide reactive group attaches specifically to free 
primary amino groups – N-termini and ε-amino groups of lysine residues [16]. 
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Figure 10. Schematic representation of the iTRAQ reagents (adapted from Applied Biosystems) 
 
 Each sample to be analyzed is tryptic digested and labeled with the single iTRAQ label after 
which sample are pooled for tandem mass analysis. The peptide product ion spectra is then 
used for the identification of the proteins and relative quantitation is derived from the peak 
intensities of the 8-plex iTRAQ reporter ions detected in the 114-121 m/z region of the 
fragmented ion spectra. Data acquired is always compared to a reference sample, and the 
quantity of each peptide is expressed as a ratio relative to the reference sample [17]. As the 
field of shotgun proteomics is evolving rapidly, it is likely to play a role in the detection of 
biomarkers. iTRAQ has been shown to permit very reliable quntitation of proteins in complex 
mixture such as plasma, serum or urine. As such it has been suggested to be a useful tool for 
the detection of biomarkers. Hence, it is likely to play a key role in this field. 
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1.5 Plasma proteomics for DS biomarker development  
Only a limited number of studies have attempted to use proteomic approaches for the 
discovery of new biomarkers for pregnancies at-risk of carrying a fetus with DS. Two of these 
used 2-DE (see above) approaches [21, 22], while a further used a SELDI method [23]. Of 
these studies that by Nagalla and colleagues is the largest, having examined serum samples 
from 56 pregnant women. This study used samples collected in both the 1st and 2nd trimester 
of pregnancy, which were recruited as part of the NIH funded FASTER study, and largely 
made use of the fluorescent 2D-DIGE process. In their study, 18 proteins were found to be 
elevated in 1st trimester samples, which included members of the apoliprotein family, 
clusterin and proteins involved in skeletal development (tetranectin). None of the identified 
marker proteins attained any specificity in a blinded analysis of maternal serum samples. 
The study by Kolialexi and colleagues [21] used traditional 2DE stained with Coomassie blue 
on 20 maternal plasma samples (8 cases, 12 controls, 16-18 weeks of pregnancy), by which 
means 8 candidate proteins were detected. Elevations were noted for apoliprotein E and serum 
amyloid P-component. In contrast to the study by Nagalla et al., [22] a down regulation for 
clusterin was noted.  
The drawback or merits of the various approaches, as well as future development are 
discussed in detail in our review on this topic [24]. 
In our experimental analysis we determined that the use of isobaric tagging (iTRAQ) was the 
most promising for the quantitative analysis of changes in the maternal plasma proteome in 
DS affected pregnancies. This approach forms a major part of this thesis (refer to section 3 
and 5).  
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1.6 Preeclampsia  
Preeclampsia (PE) is a severe disorder of pregnancy and a major cause of fetal and maternal 
mortality. It occurs almost 3-5% of pregnancies in developed countries, and is considerably 
higher in less developed nations. The clinical symptoms include rapid hypertension in 
previously normotensive women, as well as excess protein in urine. Other symptoms may 
include oedema, severe headache and liver or kidney dysfunction [25]. 
The underlying aetiology of PE is unknown, but involves aberrant placentation. Frequently 
the only therapeutic option is delivery of the baby and removal of the placenta, upon which 
most cases with PE resolve. This, however, leads to the delivery of very premature fetus, 
which is frequently affected by growth retardation. A major clinical concern is that no reliable 
method exists to detect at-risk pregnancies, and hence, a many efforts are expended for the 
development of new screening biomarkers. It is hoped that these markers will facilitate better 
management of at-risk pregnancies, by permitting early therapeutic intervention [26]. 
Amongst the markers currently being explored are angiogenic factor like soluble fms-like 
tyrosine kinase-1 (sFLT), placental growth factor (PIGF), vascular endothelial growth factor 
(VEGF) [27] and endoglin which are produced by placenta, and whose abnormal expression 
are thought to play a role in the hypertensive symptoms. Unfortunately changes in these 
molecules only appear to occur in the 2nd trimester of pregnancy very shortly before onset of 
symptoms [28]. 
Apolioprotein E (ApoE) is a major constituent of very low-density lipoprotein. As it has been 
hypothesised that preeclampsia may developed because of abnormal lipid metabolism, 
leading to oxidative stress, ApoE may play a role in this cascade. In this context it has been 
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observed that women with PE have an abnormal lipid profile, which contributes to endothelial 
dysfunction [29]. 
Inhibin A and Activin A are placentally produced glycoproteins that have been reported as 
possible predictors for preeclampsia [30], although this may be limited to the 2nd trimester, 
where elevations in inhibin A have been noted. First trimester inhibin A analysis has been 
shown to have a low predictive value [31].  
Pregnancy-associated plasma protein A (PAPP-A) is highly glycosylated protein and 
produced by the developing trophoblast. Lower levels of PAPP-A appear to be present in first 
trimester serum of pregnant women who subsequently develop PE, however, its specificity 
has been questioned as alterations are also observed in other pregnancy related conditions 
[32].  
Hence, the quest continues for biomarkers that possess predictive value even in the 1st 
trimester of pregnancy. 
One of the most promising of those currently being examined is placental protein 13 (PP13), a 
short diamer protein (32-kDa), which is highly expressed in placenta. During normal 
pregnancy PP13 expression gradually increases with the gestational age [33]. Of interest is 
that PP-13 expression is lower in women who subsequently develop preeclampsia when 
compared to healthy controls [34]. The efficacy of PP-13 as a screening marker was 
investigated in the EU funded Pregnancy project, in which our lab participated, and which 
funded a large part of this thesis.  
1.6.1 Plasma Proteomics for new screening biomarkers for Preeclampsia  
As discussed above, currently no reliable early screening marker exists for the prediction of 
preeclampsia.  It is our hypothesis that as the placenta is in close contact with the maternal 
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circulation, and as preeclampsia is associated with placental alterations, that these could be 
detectable via analysis of the maternal plasma proteome. Such biomarkers could then be used 
for the early detection of at-risk pregnancies, and thereby could assist with better management 
of these. In our study we examined 1st trimester maternal plasma samples by quantitative 
proteomic analysis using isobaric tagging for the detection of putative biomarkers.  
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2.1 Abstract 
Objectives: To examine whether there is difference in pre- and post-delivery maternal plasma 
proteome by shotgun proteomics. 
Methods: Blood samples were collected from pre- and 24 hr post- delivery sample. Plasma 
extracted from the sample was subjected to 2 different types of pre-fractionation techniques, 
namely immuno-depletion and free flow electrophoresis (FFE). Tryptic peptides were 
analysed using mass spectroscopy (LC-MS/MS). 
Results: Eleven plasma proteins were detected in pre delivery sample, which were absent 
from the post delivery sample. 
Conclusion: FFE and immuno-depletion are efficient system for pre-fractionation of maternal 
plasma samples to remove albumin, thereby permitting the detection of changes in the 
maternal plasma proteome which occur following delivery. 
 
Keywords: Free Flow Electrophoresis, maternal plasma, shotgun proteomics 
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2.2 Introduction:  
A successful pregnancy outcome depends on many different factors, which includes the 
physiologic implantation of the placenta. The placenta is a dynamic organ which increasingly 
nurtures the developing fetus with required nutrients and oxygen. It also helps to protect the 
fetus against potentially adverse maternal immune responses [35]. The placenta is the direct 
interface between the mother and developing fetus [36]. In this context it is noteworthy that a 
number of pregnancy related disorders, such as preeclampsia, preterm labour or even fetal 
aneuploidies, are associated with placental anomalies, which can contribute to the underlying 
pathology. Furthermore, there is continuous shedding of trophoblast-derived micro-particles, 
as well as liberation of cell-free nucleic acids and trophoblast deportation into the maternal 
circulation by the placenta during almost all stages of fetal development [37]. Hence, and 
analysis of the maternal plasma proteome for placenta-derived peptides may yield important 
biological clues regarding various physiological and pathological states of fetal development 
[38]. 
The aim of this study was to examine whether changes in the maternal plasma proteome 
occurred as a result of delivery, due to removal of the placenta. For this purpose we examined 
maternal plasma samples taken prior to and 24 hrs post removal of the placenta by before and 
shotgun proteomics. This analysis permitted s to ascertain whether we could detect placenta 
specific peptides and whether these were cleared from the maternal circulation post delivery.  
In this study, we also attempted to optimize the method for the depletion of major abundant 
proteins in plasma, as these are a great hindrance when desiring to detect less prevalent 
peptides, such as those of fetal origin. We used the two commercially available depletion 
column systems and the recently described Free Flow Electrophoresis (FFE) system [39]. FFE 
essentially operates on the principal of isoelectric focusing (IEF). The usefulness of this 
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system is that it permits the clear separation of albumin from the remaining plasma proteins 
[40]. 
2.3 Material and Methods: 
Urea was purchased from Serva (Heidelberg, Germany). Sodium hydroxide, sulphuric acid 
were purchased from Rield-de-Haen (St. Louis, Mo, USA). DL-2-Aminobutyric acid, glycyl-
glycine, ethanol-amine, 6-aminohexanoic acid, and N-acetylglycine were obtained from Fluka 
(St. Louis). HEPES, AMPSO, and acetic acid were purchased from Roth (Karlsruhe, 
Germany). ß-Alanin was obtained from Sigma-Aldrich (St. Louis). TAPS were purchased 
from CalBiochem (Darmstadt, Germany). Sequencing grade trypsin was purchased from 
Promega (Madison, WI, USA). FFE reagent, IEF prolyte Buffer2, IEF Prolyte Buffer 3-9, and 
2-(-4 sulfophenylazol)1,8-dihydroxy-3,6-naphthalene di-sulfonic acid (SPADNS) were 
bought from BD Diagnostics (Munich, Germany). SepPak cartridges were purchased from 
Waters (Milford, MA, USA). Ultrafilteration spin columns (MWCO 3 kDa) were bought from 
Vivascience (Hannover, Germany). 
2.4 Samples  
This study was approved by the Institutional Ethical Board of the University Hospital Basel, 
Switzerland. Informed consent was taken from all the pregnant women who participated in 
the study. Blood for this study was collected from six low risk pregnant women with singleton 
pregnancies prior to and 24 hrs after an elective caesarean section. In this manner, the plasma 
proteome was not influenced by the effect of labour. 
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Characteristic   Case (n=6)   
Maternal age, (y)   35.1±1.3   
Gestational age, (wk)   38.8±0.8   
 
Table 1. Clinical details of the pregnancy cases used for the study 
2.5 Sample preparation 
9 ml blood was drawn into BD P100 tubes (BD Diagnostics, Franklin Lake, NY, USA), 
which are specially designed for the proteomic analyses [39]. EDTA and protease inhibitor, 
present in the tube, prevent coagulation and stabilize plasma proteins. Tubes were centrifuged 
at 3,000x g for 30 minutes at 10ºC. Plasma was separated from maternal erythrocytes and 
leukocytes by a mechanical separator. Small 100µl aliquots of plasma were transferred in 
Eppendorf tubes and stored at -80ºC until further processing.  
2.5.1 Immuno-depletion 
To remove the most abundant proteins present in the maternal plasma samples, we made use 
of commercially available columns, which either depleted fourteen (MARS Human-14, 
Agilent) or twenty (Proteoprep 20, Sigma-Aldrich) of these proteins. Both systems were used 
according to the manufacturer’s instructions. 
2.5.2 Free Flow Electrophoresis (FFE) 
Electrophoresis was performed in isoelectric focusing (IEF) [40] mode using a BD™ FFE 
system (BD diagnostics) [41]. In brief, all the media were prepared fresh for the run according 
to the manufacturer’s instructions. The media used for the IEF run contained 8 M Urea. The 
counter flow media (inlet 1-3) was made by 8M urea with no prolyte addition. Anode 
stabilization buffer (inlets 1 and 2) consisted of 100 mM sulphuric acid, 50 mM acetic acid, 
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100 mM DL-2aminobutytic acid and 30 mM glycyl-glycine; Depletion buffer 1 (inlet 3 and 5) 
contained 29% of prolyte buffer 2 (BD Diagnostics); depletion buffer 2 contained 17% 
prolyte buffer 2, 50 mM HEPES, and 42 mM 6-aminohexanoic acid; and cathodic 
stabilization buffer (inlets 6 and 7) 100 mM sodium hydroxide, 30 mM ethanolamine, and 300 
mM ß-alanin; anode and cathode electrode buffer contained 100 mM sulphuric acid and 
sodium hydroxide respectively.  
The instrument was operated in horizontal mode with a spacer of 0.4 mm and the filter paper 
of 0.6 mm thickness. During entire depletion electrophoretic run the temperature was 
maintained at 10ºC and the media flow rate was set at 60 ml/h, with a constant voltage of 700 
V. Prior to electrophoresis, 500 ul of plasma was diluted ten times with the depletion buffer 2 
and was introduced into the instrument from the sample port. After the fractionation, samples 
were collected in a 96 well plate. About 2 ml of each fraction was collected. A volume of 500 
ul of the each FFE fraction 24-33 was reduced in 10 mM TCEP for 60 min at 25ºC and 
alkylated in the dark in 50 mM iodoacetic acid for the 60 min at 25ºC. The pH was adjusted to 
7.8 with ammonium bicarbonate and the urea concentration was reduced to approximately 2 
M using an ultra-filteration spin column Vivascience (Hannover, Germany). 
2.5.3 Mass Spectroscopy analysis 
The pooled FFE peptide fraction, as well as those from the immuno-depletion columns were 
digested with trypsin (100 ng) at 37ºC for 16 h. Sep Pak™ C18 RP cartridges were used to 
purify the peptides. The peptides were analysed by capillary liquid chromatography tandem 
MS (LC/MS/MS) using a 300SB C-18 trap column (0.3x50mm) (Agilent Technologies, 
Basel, Switzerland) connected to a 0.1 mm x 10 cm capillary separation column packed with 
Magic C18 (5 µm particle diameter). The capillary column was connected to an Orbitrap FT 
hybrid instrument (Thermo Finnigan, San Jose, CA, USA). A linear gradient from 2 to 60% 
solvent B (0.1% acetic acid and 80% acetonitrile in water) in solvent A (0.1% acetic acid and 
2% acetonitrile in water) in 85 min was delivered with a Rheos 2200 pump (Flux Instruments, 
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Basel, Switzerland) at a flow of 100 µl/min. A pre-column split was used to reduce the flow 
to approximately 500 nl/min. 10 µl sample was injected with an autosampler, thermostated to 
4°C onto the trap column for efficient desalting. The eluting peptides were ionized at 1.6 kV. 
The mass spectrometer was operated in a data-dependent fashion so that peptide ions were 
automatically selected for fragmentation by collision-induced dissociation (MS/MS) in the 
Orbitrap. The MS/MS spectra were then searched against the data bank using TurboSequest 
software [42]. 
2.6 Two-Dimensional Gel Electrophoresis  
We performed the two dimensional electrophoresis on the immuno-depleted plasma, as well 
as FFE depleted pooled fractions (24-33) using an ISODALT system. In this run, ampholine 
pH 3-10 (Invitrogen) in the first dimension; and 11-19% linear acrlyamide gradient in the 
second dimension was used. After electrophoresis the gels were stained with silver stain, and 
then scanned by Pharmacia Image Scanner at 300 dpi, 16 bit [43]. 
2.7 Results  
In this study we examined for differences in the maternal plasma proteome following deliver 
via the use of shotgun proteomics. Samples were obtained from 6 cases with singleton 
pregnancies, all of which were delivered by voluntary Caesarean section. Care was taken to 
maintain the uniformity in the collection time for all the samples.  
In the analysis of un-depleted maternal plasma samples, a 2µl volume from a pre- and post-
delivery was examined by 4-12% SDS-PAGE. Following silver staining, it became apparent 
that the presence of the most abundant proteins  
Such as albumin, or immunoglobulins, totally masked the presence of other less abundant 
proteins (refer to Figure1).  
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Figure 1. Undepleted maternal plasma from (a) pre and (b) post delivery. A volume of 2µl was loaded on the 4-
12% SDS-PAGE. M represents the protein marker 
 
In order to overcome this problem, we next examined whether we could deplete these 
abundant plasma proteins, which contribute more than 99% of the plasma proteome, by using 
commercially available immuno-affinity columns. We examined two different column 
systems which either have the ability to deplete fourteen (MARS Human-14, Agilent) or 
twenty (Proteoprep 20, Sigma-Aldrich) major plasma proteins (refer to Figure 2. (A) and (B) 
respectively). 
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Figure 2. Two dimensional electrophoresis of depleted maternal plasma was preformed in the ISODALT system. 
After electrophoresis, the gels were sliver stained. (A) Depletion of fourteen major plasma protein.(MARS 
Human-14, Agilent). (B) Depletion of twenty major plasma proteins (Proteoprep 20, Sigma-Aldrich). 
 
We determined that although these immuno-depletion columns did permit reliable removal of 
the most abundant plasma proteins, their use entailed a large number of washing steps which 
resulted in low recovery of the desired placenta-derived proteins. 
In order to improve the recovery of these rare proteins species, we next examine the efficacy 
of a recently described Free Flow Electrophoresis system, which operates on the principal of 
isoelectric focussing (IEF) [44]. By the use of this technology, we were able to confine 
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albumin into certain fractions (numbers 37-40), as is illustrated in Figure 3. The system was 
used under denaturing conditions.  
  
 
 
 
Figure 3. Separation of plasma using FFE protocol. SDS-PAGE (4-12%) analysis of the FFE fraction obtained 
using the depletion protocol. Proteins were visualized by silver staining. Albumin has a molecular mass of 
almost 50 kDa. A volume of 5 µl was loaded per FFE fraction. M indicates protein molecular weight marker.  
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After mass spectrometric analysis of acidic (fractions 26-33) and alkaline pool (fractions42-
49), we were able to identify 51 unique proteins in pre- and 71 proteins in post-delivery 
samples. Of these, eleven of the proteins were present in the pre-delivery samples, which 
were absent in post-delivery samples (refer to Table 2).  
 
 
 Table 2. List of proteins identified in pre-delivery maternal plasma, but absent 24 hour post-delivery. 
Metalloproteinase activity Carnosinase 1 Q96KN2 
Immuno response Immunoglobulin lambda light chain VLJ region P15814 
Complement system Complement component 4 binding protein P0C0L4 
Complement system Complement factor H P00736 
Complement activity C1q B-chain P02746 
Transporter activity  Transferrin  P02787 
Signal for cellular binding Apolipoprotein B-100  P04114 
Signal transduction Angiotensinogen  P01019 
Transcriptional regulator Galectin 3  P17931 
Complement activity Alpha-2-macroglobulin  P01031 
Signal transduction Fibrinogen, alpha polypeptide isoform alpha-E  P02671 
Molecular function 
 
Protein Name 
 
Accession no. 
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2.8 Discussion: 
In this pilot study set out to examine whether changes in the maternal plasma proteome were 
apparent following delivery (24 hr). In order to remove the most abundant proteins, such as 
albumin, which mask the rare placentally-derived proteins from the maternal plasma sample 
we tested two strategies. In the first we examined the use of two different commercially 
available immuno-depletion columns, that either remove 14 (MARS Human-14, Agilent) or 
twenty (Proteoprep 20, Sigma-Aldrich) of the major plasma proteins.  
Our experience indicated that although though these immuno-depletion columns are 
convenient to use, they do not permit optimal recovery or rare plasma proteins due to a large 
number of washing steps. 
In the second strategy we examined the use of a Free Flow Electrophoresis system. In our 
experience this system permits a more optimal recovery of rare plasma proteins, as it permits 
the effective removal of albumin, which constitutes almost 99% of the total plasma protein. 
Furthermore, this system permits the fractionation of large plasma volumes (up to 3ml/h), 
thereby permitting large-scale analyses. 
A further advantage of the FFE system is that in the denaturing mode, it permits the recovery 
of proteins which normally bind to albumin, and which would as such be removed by 
methods relying on immuno-depletion. Consequently, it should permit the more optimal 
recovery of rare proteins that would be achieved when using immuno-depletion strategies. 
[45]. 
In our analysis of pre- and post delivery maternal plasma samples we were able to detect 11 
proteins present in the former, but absent in the latter. Amongst the proteins we detected was 
angiotensinogen (P01019) [46], which plays a physiological role in the regulation of 
uteroplacental blood circulation. Alterations in the levels of this protein, as well as auto-
antibodies directed against the receptor have been implicated in the underlying aetiology 
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leading to the development of preeclampsia Alpha-2-macroglobulin (P01031) is also 
noteworthy, as a number of studies have indicated that it may play possible role in pregnancy  
Two proteins known to be expressed in the placenta are galectin 3 (P17931) [47] and 
Apolipoprotein B-100 (P04114) [48]. Galectin 3 has been shown to be present in all 
trophoblastic lineages including villous cytrotrophoblast and extravillous trophoblasts. 
Apolipoprotein B-100 (P04114) [48] has been shown to be synthesized and secreted by the 
placenta. The detection of transferrin (P02787) [49] is also significant, as this is a very 
important iron transport protein, responsible for the transfer of iron from mother to the fetus. 
An elevation in the inflammatory response markers, such as C-reactive protein [50] and 
members of the immunoglobulin family such Ig lambda chain C region were present in pre-
delivery samples, but absent in post-delivery samples, which could be indicative of an 
increased inflammatory response associated with the onset of labour towards the end of 
pregnancy.
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3.1 Abstract 
A current major obstacle is that no reliable screening markers exist to detect pregnancies at 
risk for preeclampsia. Quantitative proteomic analysis employing isobaric labelling (iTRAQ) 
has been suggested to be suitable for the detection of potential plasma biomarkers, a feature 
we recently verified in analysis of pregnancies with Down syndrome foetuses. We have now 
examined whether this approach could yield biomarkers to screen pregnancies at risk for 
preeclampsia. In our study, we used maternal plasma samples obtained at 12 weeks of 
gestation, six from women who subsequently developed preeclampsia and six with 
uncomplicated deliveries. 
In our analysis, we observed elevations in 10 proteins in the preeclampsia study group when 
compared to the healthy control group. These proteins included clusterin, fibrinogen, 
fibronectin, angiotensinogen, increased levels of which are known to be associated with 
preeclampsia. An elevation in the immune-modulatory molecule, galectin 3 binding protein, 
was also noted. Our pilot study, therefore, indicates that quantitative proteomic iTRAQ 
analysis could be a useful tool for the detection of new preeclampsia screening markers. 
  
 
 
Key words: iTRAQ (Isobaric Tags for Relative and Absolute Quantitation), preeclampsia, 
maternal plasma, biomarker, screening. 
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3.2 Introduction 
Preeclampsia is a major health concern, as it is a leading cause of fetal and maternal mortality 
and morbidity, worldwide. A major clinical deficit is that no reliable screening markers exist 
to detect at-risk pregnancies, thereby offering no opportunity for intervening therapies prior to 
the onset of symptoms. This is especially relevant for severe cases of early onset forms of the 
disorder, resulting in the delivery of premature babies, who are frequently affected by intra-
uterine growth retardation. 
It is widely accepted that the underlying aetiology of this enigmatic disorder, characterised by 
sudden hypertension in previously normotensive pregnant women, involves the placenta. In 
this context, the placentae of early onset preeclampsia are usually characterised by 
abnormalities in trophoblast differentiation, lack of modification of the maternal spiral arteries 
and ill-defined villous structure.  
Recent studies have indicated that the clinical symptoms, such as hypertension and 
proteinuria, are largely brought about by alterations in the levels of angiogenic factors 
produced by the placenta such as placental growth factor (PIGF), vascular endothelial growth 
factor (VEGF), soluble Flt-1 and endoglin [51] Although alterations in the levels of these 
cytokines do precede the onset of clinical symptoms, it is not clear how effective they will be 
as screening markers, as these changes occur relatively late in gestation. 
A considerable effort in prenatal medicine is being devoted to the development of efficacious 
first trimester screening tools, to detect pregnancies at risk for fetal aneuploidies, but also 
pregnancy-related disorders such as preeclampsia, as this would permit sufficient time for 
intervention. In this regard, quantitative changes at 11-14 weeks of pregnancy in proteins such 
as ADAM-12 [52], PP-13 (placental protein -13) [53, 54], pregnancy-associated plasma 
protein-A (PAPP-A) in combination with Doppler ultrasound, have been shown to posses 
some predictive value in detecting cases at risk for preeclampsia [32]. 
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Since the aetiological cascade leading to the development of manifest preeclampsia is multi-
factorial, it is very unlikely that a single molecule (or small group of analytes) will possess 
sufficient sensitivity and specificity. Hence, new strategies will need to be explored in order 
to increase the pool of biomarker candidates. 
One such route is by proteomic analysis of the maternal plasma proteome. The underling 
rationale for such investigations is that as the placenta is in direct contact with the maternal 
circulation, proteins released by it should be detectable in maternal plasma. Since 
preeclampsia is associated with structural placental anomalies, the underlying alterations in 
protein expression should be reflected in plasma proteome. Consequently, this serve as a 
promising route for the detection of biomarkers indicative of abnormal placentation [55]  
Consequently, a number of studies have been carried out under this premise, and have shown 
that alterations in protein expression are evident maternal serum or plasma of affected 
pregnancies. Unfortunately the validity of these studies is limited, as they were performed on 
samples obtained from cases with manifest symptoms, and furthermore, did not employ state-
of-the-art quantitative approaches permitting precise assessment of the extent of up- or down-
regulation of the newly discovered markers. 
A further limitation in these studies is the extremely complex nature of the plasma / serum 
proteome, whereby low abundance proteins are masked by the preponderance of a small 
number of highly abundant plasma proteins. In addition, the high dynamic range of the 
plasma proteome precludes the use of conventional proteomic strategies employing gel 
electrophoresis, even when making use of fluorescent labelling e.g. DIGE (Difference Gel 
Electrophoresis). Hence, the identification of new biomarkers in plasma/serum by 
conventional proteomic approaches is not very feasible.  
A method that has been proposed to largely overcome these deficits is isobaric labelling 
(iTRAQ: Isobaric Tags for Absolute and Relative Quantitation) coupled with MALDI 
TOF/TOF analysis. In this approach, the plasma peptides, following trypsin digestion, are 
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chemically labelled with a discrete set of isotopes via an amine-tagging reagent. These isotope 
tags permit ready discrimination by mass spectrometry, thereby permitting comparative 
quantification to a reference sample in a multiplex manner. To date, most applications have 
made use of commercial 4-plex reagents, but 8-plex reagents are becoming available. By the 
use of these different isobaric tags, it is possible to examine 4 or 8 different samples in a 
single mass spectrometric analysis.  
Since this method has been shown to permit highly reproducible comparative assessment of 
tagged peptides, it has been suggested to be suitable for the discovery of biomarkers in 
complex body fluid PE such as plasma. In a recent study we have shown that the iTRAQ 
isobaric labelling approach may indeed be valid for the detection of biomarkers for pregnancy 
related conditions, such as fetuses with Down syndrome, in that we were able to discern 
quantitative alterations in known screening markers such as βhCG [56].  
Confident by the validity of the iTRAQ methodology, we have now in a pilot experiment 
investigated whether this approach could be suitable for the detection of biomarkers useful for 
determining pregnancies at risk for preeclampsia. In this study we examined 12 maternal 
plasma samples obtained at 12 weeks of pregnancy, of which 6 cases subsequently developed 
preeclampsia, while 6 cases had uncomplicated deliveries.  
 
Maternal plasma peptides were examined by 4-plex iTRAQ labelling in conjunction with a 
4800 MALDI TOF/TOF analysis. Our results indicate that quantitative differences can be 
already being detected in the first trimester of pregnancy between pregnancies which 
subsequently developed preeclampsia and those which had normal healthy outcome. 
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3.3 Materials and Methods 
3.3.1 Samples  
Blood samples for this case-control proteome study were collected prospectively from 
pregnant women at approximately 12 weeks of gestation. In a retrospective manner, 6 
samples from cases that subsequently developed preeclampsia were matched with 6 samples 
from pregnancies with normal healthy outcome (Table 1). This study was undertaken with the 
approval of the Institutional Ethical Board of the University Hospital, Basel, Switzerland and 
written informed consent was required in all instances. 
(A) 
 Control PE 
Maternal age (years) 35.1±1.3 35.1±6.8 
Gestational age (weeks) 38.8±0.8 34.9±2.4 
Systolic BP (mmHg) 122.5±14.2 188.8±18.6 
Diastolic BP (mmHg) 73.6±7.0 111.8±14.1 
Proteinuria (dipstick) Negative  +++ 
 
(B) 
 Control PE 
Gestational age (weeks) 12.4±1.2 12.3±1.1 
 
Table1. Characteristic of study population. (A)Criteria used for pregnancy with or without preeclampsia for the 
longitudinal study. (B) Gestational window selected for the current study (n=6) who subsequently developed the 
preeclampsia 
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3.3.2 Sample preparation 
As described previously, 9 ml blood was drawn into BD P100 tubes (BD Diagnostics, 
Franklin Lake, NY, USA), which are specially designed for proteomics experiments, in that 
the EDTA (Ethylenediaminetetraacetic acid) and protease inhibitor present in the tube prevent 
coagulation and stabilize the plasma proteome. Following phlebotomy the samples were 
centrifuged at 3,000x g for 30 minutes at 10ºC, whereby the plasma was separated from the 
cellular fraction by aid of a mechanical separator100µl aliquots were stored at -80ºC until 
further use. For an overview of the work-flow used in this analysis refer to Figure 1. 
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3.3.3 Immuno-depletion of High-Abundance Plasma Proteins 
Highly abundant plasma proteins were depleted using ProteoMiner™Protein Enrichment Kit 
(Bio-Rad Laboratories, Inc.), as per the manufacturer’s instructions. 1 ml of plasma was used 
for the depletion and after the whole procedure, 300 µl was eluted in elution reagent. After 
depletion protein concentration was measured by using RC-DC Protein assay kit (Bio-Rad 
Laboratories, Inc.) 
3.3.4 Tryptic digestion and iTRAQ™ Reagent labelling 
Equal amounts (100 µg) of depleted plasma protein from six of the PE cases and controls 
were pooled separately in duplicate for the iTRAQ labelling. These samples were denatured 
with 2% SPE in 500mM triethylammonium bicarbonate (TEAB) (Sigma-Aldrich) for 15 
minutes at room temperature, following which they were reduced with 2µl of 50mM tri-(2-
carboxyethyl) phosphine (TCEP) (Sigma-Aldrich) at 60°C for 1h and were then alkylated 
with 10mM s-Methylmethanethisulfonate (MMTS) for 10 minutes in room temperature. After 
alkylation, the proteins were digested overnight at 37ºC with 1U/µl trypsin (TPCK treated) 
(Applied Biosystems, Foster City, CA 94404, USA). Peptides were labelled with one unit of 
iTRAQ™ Reagent Multi-plex kit (Applied Biosystems, Foster City, CA 94404, USA) that 
was reconstituted in 70 µl of ethanol. iTRAQ labels 114, 116 were used separately for 
labelling the pooled duplicated control sample and 115, 117 were used separately to label the 
pooled duplicate preeclampsia samples. The iTRAQ labelling reagent solution was added to 
the digest and incubated for 1h at room temperature. To assess the accuracy of the ratiometric 
quantitation of iTRAQ reagent a split in signal was performed and the data was corrected as 
described in detail by Unwin and colleague [57]. 
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3.3.5 Strong cation exchange chromatography (SCX) 
Strong cation exchange chromatography was preformed to remove the excess iTRAQ reagent 
and interfering substances for the mass analysis. Dried peptides were resuspended in 200 ml 
of Buffer A and were loaded on Poly Sulfoethyl A Column (200 mm length x 4.6 id, 5 µm 
particle size, 200 Ǻ pore size) on a BioLC HPLC unit (Dionex). Buffer A consisted of 10mM 
KHPO4 and 25% acetonitrile, 500 mM KCl, pH 3.0, and Buffer B consisted of 10mM 
KH2PO4, 25% acetonitrile, and 500 mM KCl pH 3.0. The 60 min gradient comprised of 100% 
Buffer A for 5min, 5-30% Buffer B for 40 min, 30-100% Buffer B for 5min, 100% Buffer B 
for 5 min, and finally 100% Buffer A for 5 min. Ten fractions were collected using a Foxy Jr. 
Fraction Collector (Dionex). Subsequently, these fractions were pooled according to the 
chromatogram profile based on the peak intensity and the products dried in a vacuum 
concentrator, after which they were stored at -20ºC prior to mass spectrometric analysis.   
 
3.3.6 Nano LC MALDI 
The dried SCX iTRAQ-labeled peptides were dissolved in Buffer A which consist of 95% 
H2O, 5% acetonitrile, 0.1 % TFA and were loaded on C18 trap column (1mm x 300um i.d. 
column) at 30 ul/min and separated on an analytical column (150 mm x 100 um i.d. column) 
at 500 nL/min using the LC-packing Ultimate system. The peptides were separated using a 
linearly increasing concentration of acetonitrile in Buffer B from 5% to 30% in 120 min, and 
from 30% to 60% in 40 min. The elute was mixed with matrix (2 mg/ml alpha-cyano-4-
hydroxycinnamic acid in 80% acetonitrile, 0.1% TFA) at a flow rate of 800 nl/min and 
deposited on an Opti-TOF LC/MALDI (Applied Biosystems) plate in 10S fractions, using an 
automatic robot, (Probot,Dionex).  
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3.3.7 MS and MS/MS 
The Mass spectrometer 4800 plus MALDI TOF/TOF™ Analyzer (Applied Biosystems) was 
set to perform data acquisition in positive ion mode. An MS condition of 1000 shots per 
spectrum was used. Monoisotopic precursor selection for MS/MS was done by automatic 
precursor selection using an interpretation method using the12 most intense peaks per spot 
with an MS/MS mode condition of 4000 laser shots per spectrum. Minimum peak width was 
one fraction and mass tolerance was 80 ppm. Adduct tolerance (m/z) +/- 0.003. MSMS was 
done with a gas pressure of 2x10-2 bar in the collision cell Air was used as collision gas. 
Protein Identification and Database Searches:  
Protein identification and quantification was done by using the ProteinPiolt™ software v2.0 
(Applied Biosystems; MPE-Sciex). The search was performed against the Human database of 
UniProtKB/Swiss-Prot (Version 3.50) from the EBI website 
(www.ebi.ac.uk./IPI/IPIhelp.html) and concatenated target-decoy database search strategy 
was used to check the false positive rate [58] in our case it was found to be 0%, which 
boosted the reliability of our data. 
3.3.8 Relative quantitation criteria: 
The Paragon algorithm [17, 59] in ProteinPiolt v2.0 software was used as the default search 
program with digestion enzyme set as trypsin and methyl methanethiosulfonate as cysteine 
modification. The search also included the possibility of more than eighty biological 
modifications and amino acid substitution of up to two substitutions per peptide using the 
BLOSUM 62 matrix. Data was normalized for loading error by bias correction calculated 
with Progroup algorithm identified proteins with at least 95% confidence and with a 
ProtScore of 1.3, were reported. The results obtained from ProteinPilot software v2.0 software 
were exported to Microsoft Excel for the further analysis. The study was performed in double 
duplex manner, where PE samples were labelled with 115 and 117; control was labelled with 
114 and 116. Peptides were selected based on the criteria defined in the protein pilot software, 
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which means all the peptides were included for quantitation with an exception for those 
without an iTRAQ modification or reporter ion, an area count less then 40 and peptides with p 
value less then 0.001 were excluded [60]. As described by Gan and colleague in their study on 
estimation of relative quantitative ratio from iTRAQ experiments, we also used only peptides 
above or equal to 70 % confidence level for the estimation of relative quantitation [61].  
 
3.3.9 PANTHER analysis:  
The PANTHER database was used to elucidate the molecular function, biological process and 
signalling pathway associated with each individual protein 
(http://panther.appliedbiosystems.com) 
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3.4 Results 
Samples were obtained from 6 cases with subsequent preeclampsia and 6 samples from 
normal healthy deliveries. Care was taken to match both maternal and gestational age, to rule 
out any confounding influence of these two parameters. 
Low abundant plasma proteins were enriched by using ProteoMiner™Protein Enrichment Kit. 
This was accomplished through the use of a large, highly diverse bead-based library of 
combinatorial peptide ligands. When plasma was applied to the beads, a small fraction of the 
high abundance proteins saturated their high affinity ligands and the excess high abundance 
proteins were washed away. In addition a very small amount of high abundance proteins and 
low abundance proteins were concentrated on their specific affinity ligands. This provides for 
a significant enrichment of medium and low abundant plasma proteins. 
 The samples were pooled separately in and duplicate in order to have more precise analytical 
replicate measurements. The iTRAQ analysis was done in double duplex style, the PE 
samples were labelled with iTRAQ 115 and 117 and the control samples with iTRAQ 114 and 
116, using the work-flow illustrated in Figure.1. 
Following tandem MS MS, and by focussing on iTRAQ reporter ions in low molecular mass 
range (114-117Da) for quantification, we identified 200 proteins with ≥ 95% confidence. 
However, after manually rechecking the MS/MS data thoroughly peak by peak, only 167 out 
of 200 proteins (83.5%) had a relative quantitation derived from the analysis of two or more 
peptides, while for 30 proteins, the quantitation was based on single peptide. For 3 proteins no 
quantitation could be ascertained by analysis using Protein Pilot. Figure.2 shows the MSMS 
spectrum of the precursor ([M+H] +, m/z 1259.67 Da). In low mass region the reporter ions, 
are seen while the where area under of the curve was used for quantification. 
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Figure 2. Components of the spectrum illustrated are (i) MSMS spectrum of the precursor ([M+H] +, m/z 
1259.67 Da),(ii) low mass region showing the reporter ions used for quantitation. The peptide is labeled by 
isobaric tags at both the N terminus and C-terminal lysine side chain. The precursor ion and all the fragment ions 
therefore contain all four members of the tag set, but remain isobaric. The MSMS spectrum was obtained from 
the singly charged [M+H]+ peptide using a 4800 MALDI TOF-TOF analyzer 
 
As we did the experiment in double duplex manner, PE (115 and 117) and control (114 and 
116), it was possible to estimate the cut-off point for differentially expressed protein in our 
sample [60, 61]. Based on 167 relative abundant protein ratios from PE and control sample, 
an average variation of 4.4% (± 0.04) was measured. If the cut off was set at 5% average 
variance then only 75% of the proteins would fall with in this variation range, but. If the range 
was increased to 20% then about 94% of the protein falls in this variation range as illustrated 
in Figure.3. So the cut-off point in this experiment was set at 20% (±0.2). That means any 
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relative change in protein ratio below or above ± 1.2 fold was considered as differentially 
under or over expressed.  
 
 
 
Table 2. List of proteins unregulated in iTRAQ experiment 
 
The functional distribution of these proteins is illustrated in Figure.3. For this interpretation, 
an analysis of 176 proteins was performed using the PANTHER classification system, which 
sorts the proteins into respective classes based on their biological process.  
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Figure 3. Number of plasma protein identified using iTRAQ reagent. In total, 167 proteins were identified. 
Shown above is the classification of these proteins in different category based on molecular function 
 
It is of interest that three of the major groups involve cell adhesion molecules (13%), extra 
cellular matrix proteins (13%) and member of the protease family (13%), factors that are 
known to be aberrant in placental insufficiency apparent in preeclampsia. Further more large 
groups were found to involve signalling molecules (13%) and carrier proteins (20%).  
A list of 10 of the most pronounced protein differences is provided in Table 2. A PANTHER 
sub-analysis for pathway association of these 10 proteins indicates that 33% are associated 
with blood coagulation, 33% with plasminogen activation, 17% with angiotensin II and 17% 
with integrin function shown in Figure 4.  
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Figure 4. PANTHER analysis for pathway. In total, 10 proteins were identified as elevated. Shown above is the 
different signaling pathways hit by these protein. 
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3.5 Discussion: 
The comparative quantitative assessment of serum or plasma proteins via iTRAQ isobaric 
labelling combined with MALDI-TOF/TOF analysis has suggested to be suitable for the 
detection of biomarkers. This is largely due to the highly reproducible nature of the system, 
which exhibits little run-to-run variation, determined after a lengthy comparison of pooled 
and individual of case and control samples, yielding a coefficient of variation of 11.7% [20]. 
In a previous proof-of- principle study, we examined whether this approach was suitable for 
the detection of screening markers that could be sued to screen for pregnancies with a Down 
syndrome fetus [56]. This analysis indicated that this approach may indeed be valid, as we 
were capable of detecting known screening markers, since βhCG was determined to amongst 
pool of elevated proteins.  
In a preliminary proof-of-principle experiment, we have now assessed whether this method 
could be suitable for the detection of biomarkers useful for PE screening. From our small-
scale preliminary evaluation we identified over 10 proteins whose concentration was altered 
in the plasma of pregnancies with a PE compared to those with normal pregnancies.  
It is of interest that glycoprotein clustrine isoform 2 was found elevated in our study. In one of 
the recent study Blumenstein and colleague [62] has also seen the elevation in isoform of 
clusterin. Other protein like angiotensinogen, which is was reported in PE to be elevated. The 
presence of this important screening marker in our pool of elevated plasma proteins suggests 
that the strategy we have chosen for the identification of new biomarkers is functional and 
worthy of further pursuit. 
That our assay is indeed detecting proteins of placental origin is illustrated by presence of 
galectin 3which is a glycoprotein and derive its importance in pregnancy by playing potential 
role in preventing the attack from maternal immune system on the developing fetus which can 
be seen as foreign allograft [63]. This protein was amongst our list of up-regulated proteins, 
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apolipoprotein E3 isoform. The altered production of apoE3 in PE might impair reverse 
cholesterol transport contributing to arterial damage [64].  
Elevations in a number of inflammatory molecules C4 beta and fibronectin, most of which are 
probably of maternal origin, may be a reflection of the elevated release of placental debris 
which has been suggested to occur in pregnancies with PE. Williams and colleague has 
reported the elevation of and fibrinogen in PE cases [65].  
In our follow up studies we would like to validate these putative biomarkers using 
immunoblot and Enzyme linked immunosorbent assay (ELISA). More recently Selected 
Reaction Monitoring (SRM) has evolved as a method of choice for validation of biomarkers 
using mass spectroscopy. 
The increasing popularity of the iTRAQ approach due to its reproducibility and robustness, 
including studies for cancer or inflammatory autoimmune disorder specific biomarkers 
suggests that it will become the method of choice for future studies, until it is surpassed by a 
new technical development. As pregnancy represents a unique constellation, whereby a 
foreign being is supported and nourished by the host, it may serve as an ideal model for 
proteomic analyses, as any unique markers should ideally disappear post delivery. 
Furthermore, as very few specific biomarkers exist to assist with the screening of a number of 
pregnancy related disorders, especially preeclampsia or preterm labour, it is likely that this 
will become the focus of considerable research attention in the near future.  
 
3.6 Conclusion: 
In this report we conclude, isobaric labelling technique is a suitable approach for the 
quantitative detection of new screening biomarkers in the plasma of pregnancies with a PE 
compared to those with normal. In this preliminary proof-of-principle study, we were able to 
detect quantitatively under or over expressed proteins. In the future additional studies, using 
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larger sample sizes will be required to identify a panel of biomarkers which can be used in 
screening for PE pregnancies. 
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4.1 Abstract 
4.1.1 Background 
Currently no reliable 1st trimester screening method exists to detect for pregnancies which 
will develop preeclampsia. This deficit makes it difficult to develop appropriate intervention 
strategies. As the underlying placental aetiology leading to the development of preeclampsia 
is thought to occur early during gestation, we hypothesised that such changes may already be 
evident in the maternal plasma proteome. Hence, such unique proteomic fingerprints could be 
used to distinguish between pregnancies with healthy deliveries form those which developed 
preeclampsia. For this purpose we investigated the use of Surface-Enhanced Laser 
Desorption/Ionization Time-of-Flight mass spectrometry (SELDI-TOF-MS) SELDI.  
4.1.2 Results 
Unique spectral profiles were generated using SELDI-TOF-MS.A total of 8 peaks 
corresponding to peptides and proteins in the range between 3.2 kDa and 22.2 kDa were 
identified from a set of 26,707 representing the whole spectral analysis (0 to 60 kDa), were 
identified which could discriminate pregnancies with normal deliveries to those which 
developed preeclampsia.  
4.1.3 Conclusion 
Maternal plasma proteome fingerprinting by SELDI-TOF MS may lead to the development of 
a set of markers which can be used in discern pregnancies at risk for preeclampsia. 
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4.2 Introduction  
In the last two decades several biochemical and biophysical traits were identified which led to 
a considerable improvement in the screening of preeclampsia (PE). But there is no reliable 
screening biomarker for PE. So there is a need in improve both the sensitivity and specificity 
of current screening strategies. As considerable efforts has being invested in the discovery and 
development of further markers. Platforms based on proteomics [66] coupled with mass 
spectrometry (MS) techniques [21] is gaining considerable acceptance following the 
identification of different markers associated with several types of disease conditions such as 
ectopic pregnancies [67], detection chromosomal abnormalities [22, 23], ovarian cancer [68, 
69], diabetic nephropathy [70] and inflammatory bowel disease [71]. The current practice of 
using single protein biomarkers will most likely give way to the use of multiplexed 
biomarkers, as they promise better sensitivity and specificity [72]. High-throughput platforms 
using MS permit profiling large numbers of samples in relatively shorter time mostly within 
the same day of admission. Using proteomics platform to mine deep into the plasma proteome 
has resulted in the identification of several target candidates for Down’s syndrome [73, 74]. 
Moreover proteomic signatures can reduce problems with individual variability in peak 
detection [75]. We hypothesized that by using a combination of unique serum proteomic 
features (hydrophobic proteins) in protein profiles and differentially expressed proteins 
(hydrophilic proteins) could be employed to distinguish pregnancies with trisomy fetuses 
from control healthy conditions.  
 
4.3 Materials and Methods 
4.3.1 Samples  
Blood samples for this case-control proteome study were collected prospectively from 
pregnant women at approximately 12 weeks of gestation. In a retrospective manner, 6 
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samples from cases that subsequently developed preeclampsia were matched with 6 samples 
from pregnancies with normal healthy outcome (Table 1). This study was undertaken with the 
approval of the Institutional Ethical Board of the University Hospital, Basel, Switzerland and 
written informed consent was required in all instances. 
 
4.3.2 Sample preparation 
As described previously, 9 ml blood was drawn into BD P100 tubes (BD Diagnostics, 
Franklin Lake, NY, USA), which are specially designed for proteomics experiments, in that 
the EDTA (Ethylenediaminetetraacetic acid) and protease inhibitor present in the tube prevent 
coagulation and stabilize the plasma proteome. Following phlebotomy the samples were 
centrifuged at 3,000x g for 30 minutes at 10ºC, whereby the plasma was separated from the 
cellular fraction by aid of a mechanical separator, 100µl aliquots were stored at -80ºC until 
further use. 
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(A) 
 Control PE 
Maternal age (years) 35.1±1.3 35.1±6.8 
Gestational age (weeks) 38.8±0.8 34.9±2.4 
Systolic BP (mmHg) 122.5±14.2 188.8±18.6 
Diastolic BP (mmHg) 73.6±7.0 111.8±14.1 
Proteinuria (dipstick) Negative  +++ 
 
(B) 
 Control PE 
Gestational age (weeks) 12.4±1.2 12.3±1.1 
 
Table 1. Characteristic of study population. (A)Criteria used for pregnancy with or without preeclampsia for the 
longitudinal study. (B) Gestational window selected for the current study (n=6) who subsequently developed the 
preeclampsia 
 
4.3.3 Plasma protein profiling 
Protein profiling was performed using the ProteinChip™ Biomarker System (Ciphergen 
Biosystems®, Freemont, CA, USA), a SELDI-TOF MS platform. We used H50 (C8 reversed 
phase/hydrophobic interaction chromatography) ProteinChip™ Array. Samples were applied 
to H50 protein chip arrays (Ciphergen, Fremont, CA, USA) according to the manufacturer’s 
protocol. Saturated solution of sinapinic acid in 50% acetonitrile, 0.5% trifluoroacetic acid 
was applied twice to each spot on the array, with air drying between each application. To 
minimize bias, plasma samples from mothers who developed PE and those with normal 
outcome were assayed on the same chips. Plasma samples were analyzed using the Protein 
Biology System 2 SELDI-TOF mass spectrometer (Ciphergen Biosystems). Peptides and 
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proteins below the 60 kDa range were ionized on a α-cyano-4-hydroxy-cinnamic acid matrix. 
Known proteins were used for data calibration between experiments, and the mass accuracy 
was determined daily using the Ciphergen Broad Range molecular weight standards (C100-
0001, Ciphergen Biosystems). Chips with plasma samples were analyzed under the following 
conditions: laser intensity 260V, detector sensitivity 10, mass focus 30 kDa, with molecular 
mass/charge (m/z) range from 0-60 kDa and mass optimization 3-60 kDa. Data were collected 
by averaging 65 laser shots per sample. These were exported as raw data (Ciphergen PBSII™ 
software), and used without modification for downstream bioinformatics analyses. Spectra 
were calibrated, baseline subtracted, and normalized. Qualified mass peaks (signal/noise >5; 
cluster mass window at 0.3%) within the m/z range of 2–60 kDa were selected automatically. 
Logarithmic transformation was applied to the peak intensity before analysis for biomarker 
discovery. After biomarker discovery, the quality and intensity readings of the selected peaks 
were manually reconfirmed from raw spectra. 
 
4.3.4 Bioinformatics approach 
We analyzed spectra of 6 control and 6 cases which developed PE. Each spectrum had 26,707 
mass spectral components. To reduce non-specific peaks especially in the low mass range, we 
eliminated the first 5,989 components that all corresponded to masses < 3kDa. We manually 
inspected the remaining part of the spectra and selected 62 apparent peaks in the spectra with 
the aim to select few that could be used to classify PE cases and separate them from the 
control healthy cases. These 62 peaks served to generate initial feature set based on which the 
individual cases were analyzed. 
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4.3.5 Classification process and final selection of features 
All classification tasks were done in the same fashion, distinguishing between cases which 
developed PE and those with normal deliveries, based on the Mahalanobis distance between 
the groups using the Lawrence and Solovyev algorithm [76]. We also searched for the 
minimum number of features and the small portion of the data in the training set, so as to 
achieve good generalization properties of the linear discriminate model. The process involved 
separation of each of the groups to the training part and the test part. The model is built using 
only the training data, and it is tested using the test data. 
 
4.4 Results and Discussion: 
Unique spectral profiles were generated using SELDI-TOF-MS method (Figure1). A total of 
8 spectral peaks corresponding to peptides and proteins in the range between 3.2 kDa and 
22.2 kDa were identified from a set of 26,707 features representing the whole spectra (0 to 60 
kDa) (Table 1; Figure 1a & 1b).  
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Figure 1a. Representation of peak identities corresponding to proteomic features identified using 
bioinformatics approach to discriminate healthy controls and PE cases that subsequently  
developed the preeclampsia.  
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Figure 1b. Representation of peak identities corresponding to proteomic features identified using bioinformatics 
approach to discriminate healthy controls and PE cases that subsequently developed the preeclampsia 
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Eight features were identified which could discriminate all control pregnancies from the PE – 
before onset of PE. 
 
 
Table 2. Proteomic features identified to discriminate PE conditions from normal are based on protein profiling 
technique. Y is present and N is absent for peak. 
 
Using SELDI platforms we tried to identify unique fingerprints of protein markers for 
pregnancies at risk for PE. Some studies have previously reported on the use of maternal 
serum [21, 23] and plasma [73]. The current study addresses these two important issues. 
Results from our study indicates that it might be possible to effectively screen for pregnancies 
at risk for PE using 2nd trimester maternal plasma samples and generating proteomic 
fingerprints by SELDI-TOF MS analysis.  
Protein profiling is a powerful technique to look at several hundred proteins in a single 
spectrum [18]. 
Human serum is known to contain a complex mixture of different kinds of protein and 
peptides [77], and it is suggested that a success in distinguishing healthy person from a patient 
could be improved with the identification of unique features in protein profiles [78]. The 
number of distinct features of spectral information detected in the mass spectrum of a 
processed sample is a strong indicator of the information content of the signature. Recent 
studies have focussed on using the power of SELDI techniques to study amniotic fluid, 
cervical vaginal fluid for various disease conditions associated with the developing fetus such 
as inflammation, infection [79], and neonatal sepsis and also to investigate into the 
mechanisms of idiopathic preterm birth [80]. The same approach has been used to detect 
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ectopic pregnancies [67] and as well as Down syndrome [23]. Till now this approach has not 
been explored for prenatal screening in a large scale as well as in clinical settings. In the 
current analysis, the mass (mw) of the markers ranged between 3 kDa and 60 kDa with 
majority of the markers in the range less than 22 kDa.  
4.5 Conclusions  
 
In summary, maternal plasma proteomic profiling with SELDI may prove to be a useful tool 
for the screening of pregnancies at risk for PE. The accuracy of this approach, however, 
requires large scale verification before it can be considered for clinical use. 
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6 Discussion and Outlook 
 
In this thesis, I investigated the use of a number of proteomic techniques for the purpose of 
biomarker development to screen pregnancies at risk for DS or PE. Our hypothesis for this 
approach was that both DS and PE involve structural changes in the placenta, which should be 
evident in the maternal plasma proteome, since the placenta is in direct contact with the 
maternal circulation. 
A major complication we faced when dealing with the plasma proteome, is the overwhelming 
presence of a discrete number of proteins, such as albumin, immunoglobulin, which mask less 
abundant protein species, especially those released in less prodigious quantities by the 
placenta. Strategies we took to overcome this issue included the use of a FFE device and 
commercial depletion columns. Although initially promising, the FFE approach had to be 
abandoned, due to the high concentrations of urea used in this procedure. The most successful 
approach proved to be the immuno depletion using ProteoMiner™Protein Enrichment Kit 
(Bio-Rad Laboratories, Inc.). 
As DS and PE are unlikely to lead to the production of novel proteins, but rather be reflective 
of changes in levels of protein expression, we needed a method to reliably quantify changes in 
level of potential biomarkers. In our study we examined a number of approaches, including, 
shotgun MS, SELDI and iTRAQ labelling. iTRAQ labelling has recently been suggested to be 
the method of choice when considering biomarker development. 
In our hands, this method was indeed shown to permit highly reproducible quantitation, and 
we could readily discern differences between the plasma proteome in cases with DS fetuses 
vs. controls, and well as in pregnancies at risk for PE and those with normal deliveries. 
In our analysis of DS cases we were gratified to observe that we could detect known 
biomarker molecules such as bHCG, a protein which is at the core of current screening 
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approaches, we also detected a number of other proteins, which are reflective of the changes 
occurring in DS patients, such as loose skin associated with the enlarged nuchal fold. 
Our analysis of 1st trimester samples of pregnancies at risk for PE proved more complex. Here 
we were able to detect a set of potential biomarkers, but not detect changes in new markers 
such as PP-13.This could be reflective of the small number of samples studied, or the very 
low levels of this molecule. 
The research carried out in this thesis does however demonstrate that it is possible to mine the 
maternal plasma proteome for new biomarkers. Their verification will however need to be 
carried out in much larger studies, and using more convenient techniques such as selected 
reaction monitoring (SRM) lead into outlook. 
During my thesis work, I used the fascinating method of isobaric labelling for protein 
quantitation. I will further address several projects which can be studied using quantitative 
proteomic approach. Our main emphasis will be on other chromosomal anomalies (trisomy 
13, 18, etc) and pregnancy related disorders. 
In the next leg of study, I will try to improvise the protocol for the better use of free flow 
electrophoresis (FFE) for the fractionation of tryptic peptides. We will also search for a more 
specific and highly sensitive method for the albumin fractionation. The concept of isobaric 
tagging is most promising for the fishing out the biomarkers from the complex sample like 
plasma. I would like to repeat it with bigger sample size of patients and control. 
A major focus will be to design a validation of the list of putative markers we identified in our 
studies of DS and PE. This we will do by targeted proteomics approach. One of the best 
options available is the selected reaction monitoring (SRM) [81] which is a mass 
spectroscopy based quantitation. SRM is very rapidly developing tool for the MS based 
quantitation. It exploits the unique future of the triple quadrupole. The first and third 
quadrupole act as a filter to select the ion of defined m/z and the second quadrupole is a 
collision cell. 
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Figure 1. SRM analysis on triple quadrupole. In first quadrupole the ion of particular m/z are selected in second 
quadrupole the ions are fragmented and in third quadrupole specific ion are selected for the detection. (Adapted 
from V Lange et al MSB, 2008) 
 
Picotti and colleagues [82],in there study on S cerevisia has shown the potential of SRM 
assay. They were able to detect and quantify proteins expressed to a concentration below 50 
copies/cells. In there other study [83] they have generated and apply the SRM assay for all S 
cerevisia kinases and phosphatases. 
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Figure 2. work flow for SRM assay (Adapted from V Lange et al MSB, 2008) 
 
Major advantage of SRM is it can be used for the quantitation of the less abundant peptide 
and sample fractionation is not a prerequisite for these assays. The targeted SRM approach is 
the best suited method for validation of biomarks which are identified in shotgun proteomics 
experiment. As it need to performed on more samples and validated by antibodies-based 
assays, which needs lot of time and not cost-effective. 
We have already started designing the SRM assay for the putative list of biomarks for Down 
syndrome. It will be of our interest that how these assays can be translated in clinic setting for 
the fast and reliable screening of DS and PE. 
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Urine is one of the most attractive biofluid in clinical proteomics. It is easy to collect and non-
invasive. It contains significant amount of protein and peptid which are of clinical value. We 
are also indent to check the SRM assay in urine sample from DS and PE. 
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